Large Danish Study Confirms Oral HRT Increases Blood Clot Risk, Finds Transdermal Safe

Much like the early evolution of oral contraceptives—where the sheer presence of synthetic hormones initially masked the crucial importance of specific dosing—the debate over menopausal hormone therapy has long treated the treatment as a single monolith. But a sweeping new analysis of Danish health records demonstrates that the cardiovascular safety of hormone replacement therapy (HRT) hinges almost entirely on one specific variable: how the medication enters the body.[1]

The study, published Wednesday in The BMJ, confirms that oral HRT pills are associated with a significantly higher risk of venous thromboembolism—dangerous blood clots in the legs or lungs—regardless of the dose or how long a patient takes them. However, transdermal therapies, which deliver hormones through the skin via patches, gels, or sprays, carry no such elevated risk.[1][2][3]

Researchers analyzed national registry data from Denmark covering women aged 50 to 69 between 2003 and 2021. They identified 9,807 women who suffered a venous thromboembolism, 18,460 who experienced an ischemic stroke, and 11,974 who had a myocardial infarction, matching them against tens of thousands of healthy controls to isolate the specific impact of hormone therapy.[1][2]

The results provide a highly specific quantification of the risk. According to the BMJ Group's release, taking oral hormone therapy for one year results in one extra venous thromboembolism case per 1,055 women. The overall hazard ratio for blood clots with oral therapy was 1.6, representing a 60% relative increase in risk compared to women not using HRT.[1][2]

"Current use of any oral menopausal hormone therapy was associated with an increased venous thromboembolism risk," the study authors concluded, noting that the elevated danger persisted across different regimens, daily doses, and treatment initiation ages. They added that "transdermal therapy was not associated with increased thrombotic rates regardless of regimen, active ingredients, dose, and duration of use."[2][5]

The mechanism behind this divergence is well understood in hepatology and cardiology. When estrogen is swallowed as a pill, it must pass through the liver before entering the broader bloodstream—a process known as first-pass metabolism. This liver stimulation triggers a spike in the production of coagulation factors, which promote blood clot formation.[4][5]

Transdermal patches and gels bypass the liver entirely, delivering estradiol directly into the systemic circulation. As a result, the liver is not prompted to overproduce clotting factors. The Danish registry data bore this out comprehensively, showing that the skin-based delivery route neutralized the excess clotting risk that has historically complicated HRT prescribing guidelines.[1][4]

The study also clarified the risks of stroke and heart attack, which have historically been a source of conflicting evidence. The researchers found that these specific cardiovascular events were not universally elevated by oral HRT. Instead, the increased risk of stroke (one extra case per 1,642 women) and heart attack (one extra case per 3,846 women) was strictly confined to patients taking high-dose oral estradiol—defined as more than 1 milligram per day—for longer than a year.[1][2]

For clinicians and patients, the findings offer a reassuringly straightforward path forward. Women who require systemic hormone therapy to manage severe hot flashes, night sweats, and other menopausal symptoms do not need to abandon treatment to protect their cardiovascular health, provided they use the optimal delivery method.[3][4]

The immediate clinical challenge now shifts to accessibility and prescribing habits. While the Danish registry data definitively proves the superior safety profile of transdermal delivery, patches and gels frequently carry higher out-of-pocket costs than generic oral tablets. For the risk reductions observed in this study to materialize at a population level, clinical guidelines and insurance formularies will need to formally prioritize transdermal options as the first-line standard of care for the millions of women entering menopause each year.[4]